BioLineRx Ltd. reported audited 2025 financial results with $1.2 million revenues, $2.0 million net loss, and $20.9 million cash balance providing runway into first half of 2027. The company is on track to initiate Phase 1/2a GLIX1 trial in glioblastoma by end of March 2026, received USPTO Notice of Allowance for key GLIX1 patent to 2040, and accelerated enrollment in motixafortide pancreatic cancer trial with interim readout in 2026.
Key takeaways
Net loss of $2.0 million for year ended December 31, 2025, compared to $9.2 million in 2024.
Cash, cash equivalents, and short-term deposits of $20.9 million as of December 31, 2025, runway into H1 2027.
Phase 1/2a GLIX1 trial in glioblastoma to initiate by end of March 2026 at Northwestern University, NYU Langone Health, and Moffitt Cancer Center.
USPTO Notice of Allowance for GLIX1 patent covering cancers where CDA not over-expressed, protection to 2040 plus possible 5-year extension.
Accelerated enrollment in CheMo4METPANC Phase 2b motixafortide trial in mPDAC, interim/futility analysis anticipated in 2026.
APHEXDA full-year 2025 sales of $6.7 million, providing $1.2 million royalty revenue to BioLineRx.